BPC-157 Benefits Research: Findings Observed in Preclinical Models

In a rat model of surgically transected medial collateral ligament, animals given BPC 157 (intraperitoneally, orally, or topically) showed consistent functional, biomechanical, macroscopic, and histological improvement in ligament healing relative to controls across a 90-day window (Cerovecki et al., 2010, PMID 20225319). In a transected Achilles tendon model, BPC 157 was reported to improve biomechanical, functional, and histological healing, and in vitro it was associated with increased outgrowth of cultured tendon fibroblasts (Staresinic et al., 2003, PMID 14554208). A separate Achilles tendon-to-bone detachment study reported improved functional recovery and observed that the peptide appeared to counteract impaired healing produced by concurrent corticosteroid administration (Krivic et al., 2006, PMID 16583442).

In a rat model of quadriceps tendon detachment from the muscle (a disabled myotendinous junction), BPC 157 administration was associated with reduced progressive muscle atrophy and a muscle presentation closer to uninjured controls (Japjec et al., 2021, PMID 34829776). At the cellular level, BPC 157 was reported to increase growth hormone receptor expression in cultured tendon fibroblasts at both mRNA and protein levels in a dose- and time-dependent manner (Chang et al., 2014, PMID 25415472), one of several mechanistic threads investigators have used to discuss the musculoskeletal observations.

In rat models of induced gastric ulceration, BPC 157 was associated with dose-dependent reductions in ulcer formation, with reported inhibition ratios of roughly 45.7% to 65.6% versus controls (Xue et al., 2004, PMID 15052688). In a surgically induced reflux oesophagitis model, BPC 157-treated groups were reported to show fewer polymorphonuclear and mononuclear inflammatory cells at every assessed time point over 1–4 weeks (Sikiric et al., 1999, PMID 10672991).

Work examining the distended and alcohol-instilled rat stomach reported that intragastric BPC 157 was associated with a relatively constant gastric vascular presentation compared with controls, discussed in the context of the peptide's evaluation for inflammatory bowel disease under the PL 14736 designation (Sikiric et al., 2006, PMID 17186181).

In rat crushed-muscle and transected muscle/tendon models, the angiogenic effect attributed to BPC 157 correlated with up-regulated VEGF expression in healing tissue, though no direct angiogenic effect was seen in the cell-culture conditions tested (Brcic et al., 2009, PMID 20388964). In endothelial cell and rat experiments, BPC 157 was associated with increased expression and internalization of VEGFR2 and activation of the downstream VEGFR2-Akt-eNOS axis (Hsieh et al., 2017, PMID 27847966).

In isolated rat aorta and endothelial preparations, BPC 157 was reported to induce nitric oxide generation via the Src-Caveolin-1-eNOS pathway, with the observed vasodilatory effect abolished by the NOS inhibitor L-NAME and by hemoglobin (Hsieh et al., 2020, PMID 33051481). A review of rodent studies describes the peptide as interacting with the NO system across injury models, competing with both L-arginine and its analogues (Sikiric et al., 2014, PMID 23755725).

In rat wound models and cultured cells, PL 14736 (BPC 157) was reported to enhance granulation and collagen organization and to stimulate egr-1 gene expression and its co-repressor NAB2, in some assays faster than PDGF-BB (Tkalcevic et al., 2007, PMID 17628536). In a rodent alkali-burn model, BPC-157 was associated with accelerated wound closure, increased granulation and collagen deposition, and in vitro with promotion of cell proliferation, migration, and tube formation (Huang et al., 2015, PMID 25995620).